Abstract: The present invention relates to polyclonal antibodies directed against at least one non-human biological pathogen, or against at least one molecule derived from said pathogen, towards a human or a non-human animal organism, wherein the said polyclonal antibodies are devoid of an antigenic determinant selected in a group comprising (i) N-glycolneuraminic acid (Neu5Gc) and/or (ii) a-1,3-galactose, and their use as a medicament.

Abstract: The present invention relates to a composition comprising polyclonal antibodies directed against human cells, wherein the said polyclonal antibodies are devoid of a first antigenic determinant selected in a group comprising (i) N-glycol-neuraminic acid (Neu5Gc) and (ii) ?-1,3-galactose and its use as a medicament.

Abstract: The present invention relates to the diagnosis, the prevention and the treatment of demyelinating disorders of the central nervous system (CNS), in particular disorders exhibiting altered levels of antibodies directed against ?1-3-galactose, such as multiple sclerosis (MS) and clinically isolated syndrome (CIS). The diagnosis of MS and CIS still suffers from a lack of reliable biomarkers and there is cure for these diseases, except medication acting on the immune component of the overt disease, with the usual side effects of the immunosuppression or anti inflammation intended to relieve the associated symptoms. The inventors showed that there is a significant decrease in the levels of antibodies directed against ?1-3-galactose in individuals having a MS or a CIS.

Abstract: The present invention relates to polyclonal antibodies directed against at least one non-human biological pathogen, or against at least one molecule derived from said pathogen, towards a human or a non-human animal organism, wherein the said polyclonal antibodies are devoid of an antigenic determinant selected in a group comprising (i) N-glycolneuraminic acid (Neu5Gc) and/or (ii) a-1,3-galactose, and their use as a medicament.

Abstract: The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.

Abstract: An in vitro method for determining the risk of occurrence of long-term kidney graft dysfunction in a subject comprising: a) measuring the level of CD8+ T cells having a phenotype CD45RA+/CD197?/CD27?/CD28? in a blood sample of the subject, b) comparing the level of CD8| T cells having a phenotype CD45RA|/CD197?/CD27?/CD28? measured at step a) with one or more reference values of the level of CD8+ T cells having a phenotype CD45RA+/CD197?/CD27?/CD28?, and c) determining the risk of occurrence of long-term kidney graft dysfunction in the said subject from the comparison performed at step b).

Abstract: The present invention relates to a composition comprising polyclonal antibodies directed against human cells, wherein the said polyclonal antibodies are devoid of a first antigenic determinant selected in a group comprising (i) N-glycol-neuraminic acid (Neu5Gc) and (ii) ?-1,3-galactose and its use as a medicament

Abstract: Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression of at least one gene in a sample from the subject, e.g., a blood sample, is assayed to obtain an expression evaluation for the at least one gene. The obtained expression evaluation is then employed to determine whether the subject has a graft tolerant phenotype. Also provides are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen.

Abstract: The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.

Abstract: The present invention relates to a method for detecting the presence or the absence, and optionally quantifying and/or isolating, antigen-specific peripheral blood mononuclear cells. This method, which involves flow cytometry, is based on the use of a fluorescently-labeled antibody specifically recognizing peripheral blood mononuclear cells, and of fluorescently-labeled beads coated with at least one antigen that is specifically recognized by antigen-specific peripheral blood mononuclear cells. The method according to the invention is for example useful for diagnosing immune disorders such as transplant rejections and autoimmune disorders.

Abstract: The invention relates to a method for determining a risk of permanent rejection of a graft after being transplanted to a recipient, said method being characterized in that it includes the following steps: (a) entering physiological/clinical characteristics of the recipient and the donor into a computation unit by means of an input interface, said characteristics including the gender of the recipient, the creatinine level of the graft donor when sampled, the age of the recipient at the time of the transplant,—the number of renal transplants previously received by the recipient,—a creatinine level of the recipient measured twice at at least one predetermined point in time after the transplant, a proteinuria level of the recipient measured at a predetermined point in time after the transplant, and the existence of an episode of permanent rejection of the transplant during the first year of the transplant; (b) determining the parameters on the basis of said characteristics; (c) combining said parameters so as to

Abstract: The present invention relates to a method for diagnosing chronic graft rejection of a grafted organ in a subject from a biological sample of said subject, comprising: (a) determining in vitro an expression level value for PSMB10 in said subject biological sample, (b) comparing said value to at least one reference expression level value for PSMB10 in at least one reference sample, and (c) diagnosing if said subject is or not undergoing chronic rejection of said grafted organ. The invention also concerns a diagnostic kit or microarray for performing the method of the invention. The invention further concerns the medical use of proteasome inhibitors for treating chronic rejection.

Abstract: The present invention concerns a method for the in vitro diagnosis or prognosis of a graft tolerant or graft non-tolerant phenotype, comprising: determining from a grafted subject biological sample an expression profile comprising TMTC3 gene, optionally measuring other parameters, and determining the presence of a graft tolerant or graft non-tolerant phenotype from said expression profile and optional other parameters, wherein said method does not comprise determining an expression profile comprising, in addition to TMTC3, the following 7 genes: BUB1B, CDC2, CHEK1, MS4A1, RAB30, RHOH, and SYNGR3. Said method may further comprise, if said subject is diagnosed as a graft non-tolerant subject, diagnosing from the expression profile if said subject is developing chronic rejection. The present invention also relates to a medicament comprising a TMTC3 protein, or a fragment, an analogue or an analogue fragment thereof, in particular for the treatment, prevention, delay or inhibition of graft rejection.

Abstract: The present invention concerns a method for the in vitro diagnosis of a graft tolerant phenotype, comprising: determining from a grafted subject biological sample an expression profile comprising, or consisting of, 8 genes, and optionally at least one among 41 further genes, identified in the present invention as differentially expressed between graft tolerant subjects and subjects in chronic rejection, optionally measuring other parameters, and determining the presence or absence of a graft tolerant phenotype from said expression profile and optional other parameters. Said method may further comprise, if said subject is diagnosed as a graft non-tolerant subject, diagnosing from the expression profile if said subject is developing chronic rejection. The invention further concerns kits and oligonucleotide microarrays suitable to implement said method.

Abstract: An antibody or antibody fragment directed against the CD28 receptor which blocks the interaction between B7-1 or B7-2 and CD28. Methods for blocking activation via CD28, including CD28-dependent lymphocyte activation.

Abstract: The present invention relates to a method of diagnosis and/or prognosis of an inflammatory condition, which method comprises determining the expression level of TRIB1 in a biological sample of a patient, in particular in peripheral blood or in a biopsy of a diseased tissue. Methods for treating inflammatory conditions by modulating TRIB1 expression or activity are also described.

Abstract: The invention concerns an antibody directed against the CD28 receptor and capable of blocking CD28/B7 interaction, and proteins derived from said antibody, for use in particular to block CD28-dependent activation of lymphocytes.

Abstract: The method for analyzing the activation and motivation of T cells by analysis of T lymphocyte receptors of an organism consists in the following: determination of the number of transcripts for the gene V? in order to obtain first data; amplification of the region CDR3 of the T lymphocyte receptors for each of the V? genes associated with the organism; separation of the different lengths of the CDR3 of the T lymphocyte receptors for each of the V? genes associated with the organism and estimation of the proportion of transcripts of each length of the CDR3 in each V? family in order to obtain second data; representation of the first and second data according to the V? genes and the length of the regions CDR3 in a diagram with 4 variables.

Abstract: Mean survival times of a functional transplant of solid organs in a patient are increased by administering to the patient an initial dosing of a therapeutically effective amounts of a monoclonal antibody directed against the human LFA-1 molecule in the two hours after grafting and then administering daily dosing during a period of approximately nine days.

Abstract: Stable polyligands are provided by preparing fused proteins, where the fused protein comprises a ligand at one terminus and a subunit of a multimeric unit protein at the other terminus, where the fused protein is able to assemble to provide a polyligand. The polyligands find use in modulating physiological processes by inhibiting ligand induced signal transduction by surface membrane protein receptors and/or in the case of .mu. chain use, by complement mediated killing or any other effector functions. The molecule may be composed solely, of human components to avoid an immune response by the recipient.